Lakewood-Amedex supports reintroduction of PASTEUR act

Lakewood-Amedex Biotherapeutics announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, PASTEUR, Act, legislation designed to "encourage" the development of novel therapies to address the growing global threat of antimicrobial resistance. "Antimicrobial resistance is rapidly becoming one of the greatest threats to global healthcare, making the development of novel anti-infective therapies more important than ever," said Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics. "The reintroduction of the PASTEUR Act recognizes the urgent need for innovation in this critically important field. At Lakewood-Amedex Biotherapeutics, we believe our proprietary Bisphosphocin platform represents exactly the type of differentiated antimicrobial technology needed to help address resistant microbial infections, and we look forward to advancing the development of Nu-3 in patients with infected diabetic foot ulcers."